{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:25:07Z","timestamp":1772105107178,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11060-026-05439-0","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T08:57:44Z","timestamp":1769590664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience"],"prefix":"10.1007","volume":"176","author":[{"given":"Angelo","family":"Dipasquale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasqualina","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Bosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten M. J.","family":"Wijnenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnese","family":"Losurdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Persico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Padovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Viggiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pessina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Simonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"8","key":"5439_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"issue":"4","key":"5439_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.21.02036","volume":"40","author":"NA Mohile","year":"2022","unstructured":"Mohile NA, Messersmith H, Gatson NT et al (2022) Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol 40(4):403\u2013426. https:\/\/doi.org\/10.1200\/JCO.21.02036","journal-title":"J Clin Oncol"},{"issue":"7","key":"5439_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT et al (2023) Vorasidenib in IDH1- or IDH2-Mutant Low-Grade glioma. N Engl J Med 389(7):589\u2013601. https:\/\/doi.org\/10.1056\/NEJMoa2304194","journal-title":"N Engl J Med"},{"issue":"1","key":"5439_CR4","doi-asserted-by":"publisher","first-page":"vdae003","DOI":"10.1093\/noajnl\/vdae003","volume":"6","author":"A Dipasquale","year":"2024","unstructured":"Dipasquale A, Franceschi E, Lombardi G, Simonelli M (2024) Vorasidenib in IDH mutant WHO grade 2 gliomas: time to stop sitting on the fence? Neurooncol Adv 6(1):vdae003. https:\/\/doi.org\/10.1093\/noajnl\/vdae003. Published 2024 Jan 9","journal-title":"Neurooncol Adv"},{"issue":"10","key":"5439_CR5","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1093\/neuonc\/noae107","volume":"26","author":"MJ van den Bent","year":"2024","unstructured":"van den Bent MJ, French PJ, Brat D et al (2024) The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: how should they inform treatment decisions in the era of IDH inhibitors? Neuro Oncol 26(10):1805\u20131822. https:\/\/doi.org\/10.1093\/neuonc\/noae107","journal-title":"Neuro Oncol"},{"issue":"9","key":"5439_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/neuonc\/noab088","volume":"23","author":"CMS Tesileanu","year":"2021","unstructured":"Tesileanu CMS, van den Bent MJ, Sanson M et al (2021) Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p\/19q deleted anaplastic glioma. Neuro Oncol 23(9):1547\u20131559. https:\/\/doi.org\/10.1093\/neuonc\/noab088","journal-title":"Neuro Oncol"},{"key":"5439_CR7","doi-asserted-by":"publisher","unstructured":"Vallentgoed WR, Hoogstrate Y, van Garderen KA et al (2025) Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling. Nat Cancer Aug 19. https:\/\/doi.org\/10.1038\/s43018-025-01023-z","DOI":"10.1038\/s43018-025-01023-z"},{"issue":"3","key":"5439_CR8","doi-asserted-by":"publisher","first-page":"e431450","DOI":"10.1200\/EDBK_431450","volume":"44","author":"LR Schaff","year":"2024","unstructured":"Schaff LR, Ioannou M, Geurts M, van den Bent MJ, Mellinghoff IK, Schreck KC (2024) State of the Art in Low-Grade glioma management: insights from isocitrate dehydrogenase and beyond. Am Soc Clin Oncol Educ Book 44(3):e431450. https:\/\/doi.org\/10.1200\/EDBK_431450","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"5439_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ijrobp.2023.09.008","volume":"118","author":"CJ Kinslow","year":"2024","unstructured":"Kinslow CJ, Brown PD, Iwamoto FM et al (2024) Where do we (INDI)GO from here? Int J Radiat Oncol Biol Phys 118(2):330\u2013333. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.09.008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"5439_CR10","doi-asserted-by":"publisher","first-page":"e830","DOI":"10.1212\/WNL.0000000000008877","volume":"94","author":"A Darlix","year":"2020","unstructured":"Darlix A, Rigau V, Fraisse J, Goz\u00e9 C, Fabbro M, Duffau H (2020) Postoperative follow-up for selected diffuse low-grade gliomas with WHO grade III\/IV foci. Neurology 94(8):e830\u2013e841. https:\/\/doi.org\/10.1212\/WNL.0000000000008877","journal-title":"Neurology"},{"issue":"1","key":"5439_CR11","doi-asserted-by":"publisher","first-page":"vdae189","DOI":"10.1093\/noajnl\/vdae189","volume":"6","author":"A Elia","year":"2024","unstructured":"Elia A, Roux A, Trancart B et al (2024) Watch-and-wait approach versus adjuvant treatment after radical awake resection in selected adult-type grade 3 gliomas, isocitrate dehydrogenase mutant: A case-matched cohort. Neurooncol Adv 6(1):vdae189 Published 2024 Nov 18. https:\/\/doi.org\/10.1093\/noajnl\/vdae189","journal-title":"Neurooncol Adv"},{"issue":"20","key":"5439_CR12","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1158\/1078-0432.CCR-22-1133","volume":"28","author":"MJ Mair","year":"2022","unstructured":"Mair MJ, Leibetseder A, Heller G et al (2022) Early postoperative treatment versus initial observation in CNS WHO grade 2 and 3 oligodendroglioma: clinical outcomes and DNA methylation patterns. Clin Cancer Res 28(20):4565\u20134573. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1133","journal-title":"Clin Cancer Res"},{"issue":"7697","key":"5439_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper D, Jones DTW, Sill M et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555(7697):469\u2013474. https:\/\/doi.org\/10.1038\/nature26000","journal-title":"Nature"},{"issue":"12","key":"5439_CR14","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S1470-2045(25)00534-0","volume":"26","author":"P Karschnia","year":"2025","unstructured":"Karschnia P, Young JS, Wijnenga MMJ et al (2025) A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group. Lancet Oncol 26(12):1638\u20131650. https:\/\/doi.org\/10.1016\/S1470-2045(25)00534-0","journal-title":"Lancet Oncol"},{"key":"5439_CR15","doi-asserted-by":"publisher","unstructured":"Himstead AS, Chen JW, Chu E et al (2025) Expanded use of vorasidenib in non-enhancing recurrent CNS WHO grade 3 oligodendroglioma. Biomedicines 13(1):201. https:\/\/doi.org\/10.3390\/biomedicines13010201","DOI":"10.3390\/biomedicines13010201"},{"key":"5439_CR16","doi-asserted-by":"publisher","unstructured":"Mair MJ, Werner JM, Weller J et al (2025) Prognostic stratification of newly diagnosed IDH-mutant gliomas by [18F]fluoroethyltyrosine and [11C]methionine PET - a retrospective, bicentric cohort study. Neuro Oncol. Aug 23. https:\/\/doi.org\/10.1093\/neuonc\/noaf196","DOI":"10.1093\/neuonc\/noaf196"},{"issue":"2","key":"5439_CR17","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ijrobp.2023.10.045","volume":"118","author":"TA Lanman","year":"2024","unstructured":"Lanman TA, Cao TQ, Miller JJ, Nagpal S (2024) Ready to INDIGO: vorasidenib ushers in the era of isocitrate dehydrogenase Inhibition in Low-Grade glioma. Int J Radiat Oncol Biol Phys 118(2):334\u2013336. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.10.045","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5439_CR18","doi-asserted-by":"publisher","unstructured":"Sl\u00e1vka Lukacova A, Muhic O, Str\u00f6m M, Johnsen C\u00e9line, Aubin M et al (2025) Evaluating work activity and societal burden in patients with grade 2 IDH-mutant glioma. Neuro-Oncol Pract npaf092. https:\/\/doi.org\/10.1093\/nop\/npaf092","DOI":"10.1093\/nop\/npaf092"},{"issue":"5","key":"5439_CR19","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ccell.2024.03.008","volume":"42","author":"A Spitzer","year":"2024","unstructured":"Spitzer A, Gritsch S, Nomura M et al (2024) Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma. Cancer Cell 42(5):904\u2013914e9. https:\/\/doi.org\/10.1016\/j.ccell.2024.03.008","journal-title":"Cancer Cell"},{"key":"5439_CR20","doi-asserted-by":"publisher","unstructured":"Brandon N, Rohini N, Michael DA et al (2017) Exth-34. Combined use of the pan-IDH mutant inhibitor AG-881 with radiation therapy shows added benefit in an orthotopic IDH1 mutant glioma model in vivo. Neuro Oncol 19(suppl_6):vi79. https:\/\/doi.org\/10.1093\/neuonc\/nox168.326","DOI":"10.1093\/neuonc\/nox168.326"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05439-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05439-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05439-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:47:27Z","timestamp":1772102847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05439-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["5439"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05439-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the declaration of Helsinki. The protocol received ethics approval (ONC-OSS-21-2025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The text is the sole product of the author(s) and no third party had input or gave support to its writing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 statement"}},{"value":"AD reports a relationship with Servier Medical Affairs that includes: travel reimbursement. PG reports a relationship with Servier Medical Affairs that includes: consulting or advisory. AB reports a relationship with Servier Medical Affairs that includes: travel reimbursement. MMJW reports a relationship with Servier Medical Affairs that includes: consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement. MP reports a relationship with Servier Medical Affairs that includes: travel reimbursement. GC reports a relationship with Servier Medical Affairs that includes: consulting or advisory. MG reports a relationship with Servier Medical Affairs that includes: consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement. GL reports a relationship with Servier Medical Affairs that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. MS reports a relationship with Servier Medical Affairs that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"186"}}